CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

NewsWorkgroup Activities
Written By Emily Scholler

CEOi, together with nearly 100 leading organizations as cosignatories, submitted a letter urging CMS to reconsider preliminary rates for key codes related to Alzheimer’s diagnosis.

You can read the full comment here.

Emily Scholler
Previous

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med
Next

WHO Preferred product characteristics of blood-based biomarker diagnostics for Alzheimer disease